Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension

Circulation

Volumn 94, Issue 3, 1996, Pages 477-482

  Williamson, D J ^a   Hayward, C ^a   Rogers, P ^a   Wallman, L L ^a   Sturgess, A D ^b   Penny, R ^a   Macdonald, P S ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

hemodynamics; hypertension, pulmonary; immune system; immunology; vasodilation

Indexed keywords

CAPTOPRIL; DIGOXIN; DILTIAZEM; FELODIPINE; FUROSEMIDE; GLYCERYL TRINITRATE; ISOSORBIDE; NIFEDIPINE; NITRIC OXIDE; PRAZOSIN; PROSTACYCLIN; RAMIPRIL; SPIRONOLACTONE; VERAPAMIL; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEART INDEX; HEMODYNAMICS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; VASODILATATION;

EID: 0029838867     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.3.477     Document Type: Article

References (41)

1. Bolster MB, Silver RM. Lung disease in systemic sclerosis (sclero-derma). Baillieres Clin Rheumatol. 1993;7:79-97. Review.
2. Breit SN, Thornton SC, Penny R. Lung involvement in scleroderma. Clin Dermatol. 1994;12:243-252. Review.
3. Silver R. Pulmonary hypertension secondary to systemic sclerosis (scleroderma). In: Weir SN, Archer SL, Reeves JT, eds. The Diagnosis and Treatment of Pulmonary Hypertension. New York, NY: Futura Publishing Inc; 1992:191-207.
4. Williams GH, Silman AJ. Review of UK data on the rheumatic diseases, 9: scleroderma. Br J Rheumatol. 1991;30:365-367.
5. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TJ. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986;29:515-524.
6. Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong HJ, Bein M, Smith JW, Roberts N, Cabeen W. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med. 1983;75:65-74.
7. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, Buskila D, Dutz JP, Khostanteen I, Piper S, Ramsden M, Rosenbach TO, Sukenik S, Wilkinson S, Keystone EC. Mortality in systemic sclerosis (scleroderma). Q J Med. 1992;82:139-148.
8. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992; 340:818-819. Letter.
9. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet. 1992;340:819-820. Letter.
10. Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G. Inhaled nitric oxide as a screen ing vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med. 1995;151:384-389.
11. Pepke-Zaba J, Higenbottam TW, Dinh XA, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
12. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TJ, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-205.
13. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, Levy PC, Reid LM, Vreim CE, Williams GW. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107:216-223.
14. Cigarroa RG, Lange RA, Williams RH, Bedotto JB, Hillis LD. Underestimation of cardiac output by thermodilution in patients with tricuspid regurgitation. Am J Med. 1989;86:417-420.
15. Roca J, Rodriguez-Roisin R, Cobo E, Burgos F, Perez J, Clausen J. Single-breath carbon monoxide diffusing capacity prediction equations from a Mediterranean population. Am Rev Respir Dis. 1990; 141:1026-1032.
16. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol. 1990;21:467-474.
17. Wagenwoort C, Mooi W, Corrin B. Biopsy pathology of the pulmonary vasculature. In: Gottlieb LS, Neville AM, Walker F, eds. Biopsy Pathology Series, Volume 13. London, UK: Chapman & Hall Medical; 1989.
18. Adnot S, Kouyoumdjian C, Defouilloy C, Andrivet P, Sediame S, Herigault R, Fratacci MD. Hemodynamic and gas exchange responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension. Am Rev Respir Dis. 1993;148:310-316.
19. Frostell CG, Blomqvist H, Hedenstierna G, Lundberg J, Zapol WM. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology. 1993;78:427-435.
20. Girard C, Lehot JJ, Pannetier JC, Filley S, Ffrench P, Estanove S. Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary artery hypertension. Anesthesiology. 1992;77: 880-883.
21. Roberts JJ, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation. 1993;87:447-453.
22. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399-405.
23. Purcell HJ, Gibbs JS, Coats AJ, Fox KM. Ambulatory blood pressure monitoring and circadian variation of cardiovascular disease; clinical and research applications. Int J Cardiol. 1992;36:135-149. Review.
24. Rich S, Martinez J, Lam W, Rosen KM. Captopril as treatment for patients with pulmonary hypertension: problem of variability in assessing chronic drug treatment. Br Heart J. 1982;48:272-277.
25. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol. 1992;19:1060-1064.
26. Morgan JM, McCormack DG, Griffiths MJ, Morgan CJ, Barnes PJ, Evans TW. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation. 1991;84:1145-1149.
27. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis. 1988;31:205-238. Review.
28. Miller O, Tang S, Keech A, Celermajer D. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet. 1995; 346:51-52.
29. Rozkovec A, Bernstein R, Asherson RA, Oakley CM. Vascular reactivity and pulmonary hypertension in systemic sclerosis. Arthritis Rheum. 1983;26:1037-1040.
30. Naslund MJ, Pearson TA, Ritter JM. A documented episode of pulmonary vasoconstriction in systemic sclerosis. Johns Hopkins Med J. 1981;148:78-80.
31. Fahey PJ, Utell MJ, Condemi JJ, Green R, Hyde RW. Raynaud's phenomenon of the Jung. Am J Med. 1984;76:263-269.
32. Shuck JW, Oetgen WJ, Tesar JT. Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis. Am J Med. 1985;78:221-227.
33. O'Brien JT, Hill JA, Pepine CJ. Sustained benefit of verapamil in pulmonary hypertension with progressive systemic sclerosis. Am Heart J. 1985;109:380-382.
34. Fudman EJ, Kelling DJ. Transient effect of nifedipine on pulmonary hypertension of systemic sclerosis. J Rheumatol. 1985;12:1191-1192.
35. Glikson M, Pollack A, Dresner FR, Galun E, Rubinow A. Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. Chest. 1990;98:759-761.
36. Ocken S, Reinitz E, Strom J. Nifedipine treatment for pulmonary hypertension in a patient with systemic sclerosis. Arthritis Rheum. 1983;26:794-796.
37. Alpert MA, Pressly TA, Mukerji V, Lambert CR, Mukerji B. Short-and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest. 1992;102:1407-1412.
38. Seibold JR, Molony RR, Turkevich D, Ruddy MC, Kostis JB. Acute hemodynamic effects of ketanserin in pulmonary hyperten sion secondary to systemic sclerosis. J Rheumatol. 1987;14: 519-524.
39. Sfikakis PP, Kyriakidis MK, Vergos CG. Vyssoulis GP, Psarros TK, Kyriakidis CA, Mavrikakis ME, Sfikakis PP, Toutouzas PK. Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril. Am J Med. 1991;90:541-546.
40. De la Mata J, Gomez-Sanchez M, Aranzana M, Gomezreino J. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum. 1994;37:1528-1533.
41. Niarchos AP, Whitman HH, Goldstein JE, Laragh JH. Hemodynamic effects of captopril in pulmonary hypertension of collagen vascular disease. Am Heart J. 1982;104:834-838.